Legal & General Group
INMB icon

Legal & General Group’s INmune Bio INMB Stock Holding History

Legal & General Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,520
Closed -$1.72K – 3466
2026
Q1 		$1.72K Sell
1,520
-296
-16% -$422 ﹤0.01% 3346
2025
Q4 		$2.83K Hold
1,816
– – ﹤0.01% 3364
2025
Q3 		$3.76K Hold
1,816
– – ﹤0.01% 3383
2025
Q2 		$4.2K Buy
1,816
+458
+34% +$3.36K ﹤0.01% 3394
2025
Q1 		$10.6K Hold
1,358
– – ﹤0.01% 3158
2024
Q4 		$6.34K Hold
1,358
– – ﹤0.01% 3318
2024
Q3 		$7.32K Hold
1,358
– – ﹤0.01% 3325
2024
Q2 		$12K Buy
+1,358
New +$13.4K ﹤0.01% 3246

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Legal & General Group's INMB Position: Q2 2026 in Review

Legal & General Group sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 1,520 shares — an estimated $1.72K sold.

Legal & General Group first reported a position in INMB in Q2 2024 and held it in 8 quarters. The position peaked at $12K in Q2 2024. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Legal & General Group reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 1,520 INmune Bio shares in Q2 2026, an estimated $1.72K.
  • Legal & General Group first reported a position in INmune Bio in Q2 2024 and held it in 8 quarters.
  • Legal & General Group's INmune Bio position peaked at $12K in Q2 2024.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.